PharmaEssentia (6446)
Taiwan Stock Exchange · Taiwan · prices in TWD · close of 19 Oct 2026
Key indicators
| Last close | TWD 1,175.00 |
|---|---|
| 52-week range | 452.06 – 1,645.00 |
| Return, 1 month / 3 months | −2.5% / −1.7% |
| Return, 1 year / 3 years | +110.4% / +279.6% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 44 |
| Volatility (1 year) | 55.9% |
| Worst drawdown (1 year) | -32.9% |
| Average daily value traded | 4,543.77M TWD |
| Dividend yield | 0.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
PharmaEssentia is a biopharmaceutical company based in Taiwan that develops and makes protein-based medicines, chiefly interferon therapies. Its main product is a long-acting interferon used to treat polycythemia vera, a rare blood cancer, and the company also works on treatments for other myeloproliferative disorders and related conditions. It serves patients and physicians in hematology and oncology, and its medicines are used in markets in several countries.
PharmaEssentia trades under the code 6446 on the Taiwan Stock Exchange in Taiwan, with its price quoted in New Taiwan dollars (TWD). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
PharmaEssentia (6446) trades on the Taiwan Stock Exchange in Taiwan. It last closed at TWD 1,175.00 on 19 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 308 of 1,101 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 110.4% and over the last three months it fell 1.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Taiwan Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 26.4% | ||
| From 52-week high | -25.9% | ||
| Momentum | 77 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -1.7% | ||
| 6-month return | 78.2% | ||
| 12-month return, skipping the last month | 115.8% | ||
| Stability (higher is calmer) | 34 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 55.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.9% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 4,543.77M TWD | ||
| Zero-volume days | 0.0% | ||
| Income | 4 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.1% | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.8% |
|---|---|
| 1 month | −2.5% |
| 3 months | −1.7% |
| 6 months | +78.2% |
| 1 year | +110.4% |
| 3 years | +279.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 1,299.60 / 929.56 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 57.67 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jul 2026 | TWD 1.6530 |
| 11 Aug 2025 | TWD 1.0984 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Taiwan Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.